- 1Academy of Chinese Medicine Sciences, Henan University of Chinese Medicine, Zhengzhou, China
- 2School of Medicine, Henan University of Chinese Medicine, Zhengzhou, China
- 3Department of Clinical Laboratory, Core Unit of National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Clinical use of triptolide (TP) is restricted due to severe toxicity. This study assessed the protective effect of crocin (CR) as a natural antioxidant against TP-induced toxicity in bovine collagen type II-induced arthritis (CIA) in mice. The mice in the CIA model group showed macroscopic signs of severe arthritis. The anti-arthritis effects in the control, TP + CR, and TP groups were evaluated through assessment of foot volume, arthritis score, and proinflammatory cytokines, and collagen antibody assay. Crocin reduced TP-induced toxicity, as evidenced by evaluation of survival rate, body weight, visceral index, hepatic and renal functions, histopathologic analyses, and antioxidant enzyme activities. Transcriptome sequencing resulted in identification of 76 differentially expressed genes (DEGs) associated with hepatotoxicity between the TP and TP + CR groups. Of these, Three DEGs (Cyp1a2,Gsta4, and Gstp1) were validated using quantitative real-time PCR analysis. In conclusion, CR protected CIA mice from TP-induced toxicity through modulation of the cytochrome P450 and glutathione metabolism pathways.
1 Introduction
Triptolide (TP), the most studied bioactive chemical monomer of the Chinese herb Tripterygium wilfordii Hook. F., is a highly potent and effective anti-inflammatory, immunosuppressive, anti-rheumatoid, and anticancer agent (Tian et al., 2021; Tong et al., 2021; Zhang et al., 2021; Zhao et al., 2021).
Rheumatoid arthritis (RA) is a typical autoimmune disease often with symmetric facet joint disease, characterized by synovial hyperplasia, cartilage damages, and bone erosion. The collagen type II-induced arthritis (CIA) animal model (Trentham et al., 1977), is the most commonly studied model of RA (Zhao et al., 2022). In this model, antibodies against type II collagen play a crucial role for arthritis pathology (Yabe et al., 2021). The CIA model shares many pathological and histological similarities with RA, such as synovial hyperplasia, cartilage degradation and overproduction of inflammatory cytokines (Brand et al., 2007; Liang et al., 2018).
The Chinese herb Tripterygium wilfordii Hook. F. and its extracts have been used as an anti-rheumatic in China for many years (Qin, 2019). However, TP is highly toxic, suffers from poor aqueous solubility, and induces significant adverse effects, which limits its clinical use. Therefore, there is an urgent need to reduce TP-related toxicity without affecting therapeutic potency. Many strategies have been explored, including new dosage forms, structural modifications, and combination with other Chinese herbs (e.g., TP combined with chlorogenic acid or glycyrrhizic acid (GA)) (Tan et al., 2018; Wang et al., 2018; Zeng et al., 2020; Zhang et al., 2020; Yalikong et al., 2021).
Modern pharmacological studies of saffron and its main constituents have revealed a wide spectrum of biological activities (i.e., anti-inflammatory, antinociceptive, antioxidant, immunoregulatory effects, neurodegenerative diseases, cardiovascular diseases, anticancer, anti-arthritic effects and protection against natural and chemical toxins) (Attia et al., 2021; Xing et al., 2021). Crocin, mono, and diglycosyl esters of a polyene dicarboxylic acid are some of the main active components that are responsible for the pharmacological effects of saffron (Abdi et al., 2022; Salem et al., 2022; Xu et al., 2022).
Crocin (CR) is thought to protect against toxicity of viscera induced by some materials (El-Beshbishy et al., 2012; Razavi and Hosseinzadeh, 2015). In addition, pharmacokinetic studies have shown that crocin is not bioavailable after oral administration in blood circulation. Instead, it is rapidly transformed into crocetin in the gastrointestinal tract with high relative bioavailability (Zhang et al., 2017; Hosseini et al., 2018). However, there have been no studies to evaluate combination treatment with CR and TP as this treatment strategy may potentially reduce TP-related toxicity without impacting therapeutic efficacy. Therefore, this study focused on the mechanisms by which crocin mitigates TP-induced toxicity in a mouse bovine collagen type II-induced arthritis model.
2 Materials and Methods
2.1 Drugs, Reagents, and Animals
Triptolide (purity >98%) was purchased from Xi’an Haoxuan Biotechnology Co. Ltd. (Shanxi, China). Crocin (purity >98%) was obtained from TCI Chemical Industry (Shanghai, China). Glycyrrhizic acid (GA, purity 95%) was purchased from Cool Chemistry (Beijing, China).
Bovine type II collagen (2 mg/ml), Mouse Anti-Type II Collagen IgG Antibody ELISA Kits, complete Freund’s adjuvant (CFA, 4 mg/ml), and incomplete Freund’s adjuvant (IFA, 5 ml) were purchased from Condrex ((Norcross, GA, United States). BeyoRT™ III First Strand cDNA Synthesis Kit (Cat No. D7178M, Shanghai Biyuntian Biotechnology Co., Ltd., Shanghai, China), PowerUp™ SYBR™ Green Master Mix (Cat No. A25742, Thermo Fisher Scientific, United States), and kits for analysis of creatinine (CRE, Cat No. C011-2-1), blood urea nitrogen (BUN, Cat No. C013-1-1), alanine/aspartate transaminase (ALT/AST, Cat No. C009-2-1/C010-2-1), superoxide dismutase (SOD, Cat No. A001-1), malondialdehyde (MDA, Cat No. A003-1), catalase (CAT, Cat No. A007-2-1) and glutathione (GSH, Cat No. A006-2-1) were purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). Other chemicals and reagents used were of analytical grade.
Kunming (KM) mice (male, 7–8 weeks old, 20 ± 2 g) were purchased from Huaxing Laboratory Animal Farm (Zhengzhou, China) [License No: SCXK (Yu) 20190002]. Prior to experiments, all animals were acclimated to the experimental environment for 7 days and housed in a controlled environment (25 ± 1°C, humidity of 55 ± 5%) with a 12-h light/dark cycle. The mice were allowed free access to standard diet and water during the acclimation period. The experiments performed in this study were approved by the Animal Ethics Committee In Henan University of Chinese Medicine.
2.2 Collagen-Induced Arthritis Model and Grouping
The collagen-induced arthritis (CIA) model was established using bovine type II collagen, and the clinical severity of arthritis was scored as previously described [6]. Foot volume was measured using a volume-plethysmograph (PV-200, TECHMAN,Co. Ltd., Chengdu, China). The arthritis score (or deformation index) was used to describe the shape and joint swelling of the paws of CIA mice. Total scores for each mouse greater than eight were considered successful CIA models, and all mice in the control group had arthritis index scores of 0. A schematic for the animal modeling, mode of drug administration, and subsequent procedures is shown in Figure 1. After successful modeling, the mice were randomly divided into seven groups (n = 8) as follows:
A. normal saline (Control);
B. Collagen-induced arthritis model group (CIA);
C. 300 μg/kg TP treatment group (TP);
D. 300 μg/kg TP+50 mg/kg CR group (TP + LCR);
E. 300 μg/kg TP+100 mg/kg CR group (TP + MCR);
F. 300 μg/kg TP+200 mg/kg CR group (TP + HCR);
G. 300 μg/kg TP+50 mg/kg GA (TP + GA) as the positive drug control group (Yang et al., 2017).
FIGURE 1. Schematic representation of CIA mouse model generation and treatment with TP or TP + CR. TP: triptolide; CR: crocin; CIA: collagen-induced arthritis.
A stock solution of TP was prepared in DMSO at 5 mg/ml, then diluted in saline to prepare the working solution. Doses and frequency of administration were determined during prior experiments. The animals were administered the indicated experimental treatments once every 2 days by oral gavage for 20 days (0.2 ml/10 g).
2.3 Drug Treatment Toxicity and Efficacy
Body weight, paw volume, and arthritis score were recorded during drug administration. Twenty-4 hours after the last drug treatment, the whole blood of each mouse was obtained via orbital collection. Serum was obtained by centrifugation (4°C, 3,000 rpm, 10 min). The serum levels of AST/ALT and BUN/CRE were quantified using specific commercial diagnostic kits. The levels of serum inflammatory cytokines (IL-1β, IL-6, and TNF-α) and mouse anti-type II collagen IgG were detected using ELISA kits according to the manufacturer’s instructions. The mice were sacrificed and the ankle joints were fixed in 10% formalin, decalcified, paraffin-embedded, and stained with hematoxylin and eosin (H&E).
2.4 In Vivo Drug Toxicity Study
To determine the mechanism by which CR protected against TP-induced toxicity, healthy mice were treated with TP + CR. The mice were randomly placed in the following seven groups (n = 10): A. Control (normal saline, NS); B. Low-dose TP (LTP, 100 μg/kg); C. Moderate-dose TP (MTP, 300 μg/kg); D. High-dose TP (HTP, 500 μg/kg); E. 100 μg/kg TP+100 mg/kg CR (LTP + CR); F. 300 μg/kg TP+100 mg/kg CR (MTP + CR); G. 500 μg/kg TP+100 mg/kg CR (HTP + CR). The mice were administrated the treatments daily via oral gavage for 7 days at a volume of 0.2 ml/10 g per dose. The mice were observed daily for 7 days to monitor body weight and mortality.
The mice were sacrificed and the organs (hearts, livers, spleens, lungs, kidneys, testes, stomach, and intestine) from each group were quickly harvested and washed with pre-cooled 0.9% saline solution to remove the blood. The visceral index was calculated as the ratio of visceral weight to body weight Using the following formula: Visceral index (%) = (viscera weight/body weight) × 100%. Hepatic and renal functional markers (AST/ALT and BUN/CRE) were measured as described in Section 2.3.
A portion of each sample was snap-frozen in liquid nitrogen and stored at −80°C for biochemical analysis. Portions of tissues were fixed in 10% formalin for hematoxylin and eosin (H&E) staining and visualized using a light microscope. Body weight, visceral index, histopathology, hematology, and biochemistry factors were investigated as part of the systemic toxicity evaluation.
2.5 Determination of Antioxidant Enzyme Activities
The livers were homogenized in cold saline and centrifuged at 12,000 rpm for 20 min at 4°C. The suspensions were used to assay SOD and CAT activities, and MDA and GSH levels using commercial detection kits according to the manufacturer’s instructions.
2.6 Transcriptome Sequencing (mRNA-Seq)
Liver tissues were selected from the Control, MTP, and MTP + CR groups for transcriptome studies. Library construction, mRNA-seq, and bioinformatic analysis were performed by Sinotech Genomics Co., Ltd. (Shanghai, China). The general workflow was as follows: RNA extraction and detection; mRNA enrichment and reverse transcription; cDNA purification, end repair, A-tailing, and sequencing adapters; and PCR enrichment and library construction. An Illumina NovaSeq 6000 (Illumina, United States) was used for RNA sequencing according to a previous study (Fu, Y. et al., 2020). The original data (raw reads) was trimmed to filter out unqualified sequences, then clean reads were mapped to the reference genome using Hisat2 (Hierarchical Indexing for Spliced Alignment of Transcripts, version 2.0.5). Gene abundance was expressed as fragments per kilobase of exon per million reads mapped (FPKM). Stringtie software was used to count the fragments within each gene, and the TMM algorithm was used for normalization. Differential expression analysis for mRNA was performed using R package edgeR. Differentially expressed RNAs with fold change values >1.5 and q values <0.05 were retained for further analysis, as these were considered as significantly modulated. The raw data are available under GEO: GSE202175.
2.7 Identification of Hepatotoxicity Targets
DisGeNet (http://www.disgenet.org/) and GeneCards (https://www.genecards.org/) were used to combine the relevant literature to generate a pool of hepatotoxicity targets with the keywords “hepatotoxicity or liver injury.” In the DisGeNet database, genes with EI ≥ 1 were selected. In the GeneCards database, genes with relevance scores ≥10 were selected. Finally, the combined targets were transferred from “Homo sapiens” to “Mus musculus” (https://string-db.org/).
2.8 Gene Ontology and Pathway Enrichment Analysis
Hepatotoxicity targets, differentially expressed mRNAs between the MTP group and the Control group, and differentially expressed mRNAs between the MTP + CR group and the MTP group were analyzed using a Venn diagram (http://bioinformatics.psb.ugent.be/webtools/Venn/). The intersecting genes in the Venn diagram were further investigated at the functional level. Gene Ontology (GO) analysis for biological processes, cellular components, and molecular function and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analysis were performed using STRING database. The background species was defined as “Mus musculus."
2.9 Quantitative Real-Time PCR Analysis (qRT-PCR)
The relative levels of important differentially expressed genes (DEGs) identified in mRNA seq and KEGG analyses were selected for validation using qRT-PCR. Total RNA extracted from liver tissue using Trizol reagent (Invitrogen) for mRNA-seq was used for qRT-PCR. Total RNA was converted to cDNA according to the reverse transcription kit protocol. Then, PCR amplification was performed using SYBR green PCR master mix on an ABI 7500 FAST instrument. The primers for qRT-PCR are listed in Table 1. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal reference gene. The 2-△△CT method was used to calculate the relative expression levels of the verified genes.
2.10 Statistical Analysis
All data were processed using GraphPad Prism7 software and presented as the mean ± standard deviation (
3 Results
3.1 Assessment of Drug Side Effects in Mice With Collagen-Induced Arthritis
The side effects of the administered drugs on CIA mice were evaluated for 20 days after drug administrations. The parameters measured were changes in body weight, and hepatic and renal functions. The TP group showed obvious weight reduction compared to the other groups (p < 0.001), while other groups did not significantly differ from the control group (Figure 2). TP induced weight loss was significantly reversed by CR or GA combined treatment with TP. Compared with the control group, blood serum analysis demonstrated that the levels of AST, ALT, and BUN were significantly elevated in the TP group (p < 0.01). In contrast, co-administration of TP with CR or GA mitigated the changes observed in the TP group (Figure 3).
FIGURE 3. The levels of ALT (A), AST (B), CRE (C), BUN (D) in the CIA mice liver were determined using respective kits, after 20 days of different treatment. (n = 8) **p < 0.01,***p < 0.001 vs. Control. ALT, alanine transaminase; AST, aspartate transaminase; CRE, creatinine; BUN, blood urea nitrogen; CIA, collagen-induced arthritis.
3.2 Evaluation of Therapeutic Effects in the CIA Model
Collagen-induced arthritis model mice were used to evaluate the therapeutic efficacy of TP + CR. Changes in foot volume and arthritis scores were evaluated every 3 days during drug treatment (Figure 4A,B). The foot volume and arthritis scores in the treatment groups were significantly lower than those in the model group at day 18 post-treatment (Figure 4 a,b).
FIGURE 4. Changes in arthritic foot volume ((A)/a) and arthritis scores ((B)/b) in the CIA mice through the administration course (n = 8). **p < 0.01, ***p < 0.001 vs Control. CIA: collagen-induced arthritis.
Levels of TNF-α, IL-1β, IL-6, and anti-type II collagen antibody in serum were quantitated using ELISA (Figure 5). The level of TNF-α in the serum of the model group was significantly higher than that in the control group (p < 0.05), and levels of IL-1β and IL-6 were increased, but the increases were not statistically significant. The three proinflammatory cytokines measured were reduced to different degrees in each treatment group compared with those in the model group. Anti-type II bovine collagen antibody was not detected in the control group, and was significantly increased in the model group (p < 0.001). The levels of collagen antibody were lower in each administration group compared with those in the model group (p < 0.001).
FIGURE 5. Quantitation of proinflammatory cytokines (A) TNF-α; (B) IL-1β; (C) IL-6 and anti-type II collagen antibody (D) in serum of each group using ELISA. (n = 6).
Mice in the CIA group showed macroscopic signs of severe arthritis such as deformity, swelling, and redness in the hind paw and ankle joints (Figure 6B). Foot swelling was significantly reduced in each treatment group compared with that in the Model group (Figure 6C–G). As shown in Figures 6a,b, the histological tissue sections showed that the surfaces of the ankle joints in the control group had normal morphology and smooth articular cartilage. In contrast, structural damage and edema of the ankle joint, synovial hyperplasia, and joint cavitation were observed in the CIA model group. The treatment groups showed differing degrees of improvement compared with the Model group (Figure 6C–G). In particular, the TP + CRH and TP + GA groups showed normal morphology similar to that in the Control group.
FIGURE 6. Photos of right hind paws (A–G) and histopathological analysis of ankle joints stained with H&E (a–g).
3.3 Evaluation of Toxicity of TP + CR in Normal Kunming Mice
Survival rates and body weights were evaluated 7 days after treatment administration (Figure 7). The HTP and HTP + CR groups were the only groups in which mice died. The survival rate in the HTP + CR group was significantly higher than that in the HTP group. Body weight was lower on the seventh day in all but the LTP + CR and MTP + CR groups compared with that in the control group. Treatment with MTP or HTP induced significant weight loss. Furthermore, the MTP and HTP groups showed significantly lower organ coefficients (p < 0.05), while the other groups did not significantly differ from the control group (Table 2). The weight indices of multiple organs appeared normal following co-administration of TP and CR. In addition, biochemical analysis was performed to evaluate drug-induced hepatic and renal damage. As shown in Table 3, the serum ALT/AST and BUN/CRE levels were significantly elevated following TP administration compared with those in the control and the co-administration groups. Co-administration of TP and CR group did not induce changes in serum ALT/AST or BUN/CRE compared to the control group. These results showed that administration of CR significantly mitigated TP-induced changes in hepatic and renal functions.
FIGURE 7. The survival rates (A) (n = 10) and body weight changes (B) (n = 6) of different groups over 7 days *p < 0.05, **p < 0.01 vs Control.
3.4 Crocin Alleviates Damage of Histological Structure Induced by TP Toxicity
We performed histopathological analyses of H&E-stained tissue sections from hearts, livers, spleens, lungs, kidneys, testes, stomach, and intestines. As shown in Figure 8 and Table 4, tissue injury was significantly reduced in the TP + CR group.
FIGURE 8. Histopathological observations of H&E staining on the main visceral organs of the mice. Images were obtained at 400X magnification (scale bar = 20 μm).
3.5 Determination of Antioxidant Enzyme Activities
As shown in Figure 9, the activities of hepatic CAT and SOD, and the levels of GSH and MDA, were measured in each group. Hepatic SOD and CAT activities, and GSH content, decreased in a TP dose-dependent manner (p < 0.01). There were no significant differences between the TP + CR group and the control groups. Moreover, MDA content was higher in the MTP and HTP groups than in the control group (p < 0.05). However, there was no significant difference in MDA content in the liver between the TP + CR group and the control group.
FIGURE 9. Levels of CAT (A), SOD (B), GSH (C), and MDA (D) in liver homogenates of mice (n = 6). *p < 0.05, **p < 0.01, ***p < 0.001 vs Control.
3.6 Differentially Expressed mRNAs and KEGG Analysis
Expression profiling studies were performed on the RNAs from four independent liver tissue samples in each group. The volcano plot of differentially expressed mRNAs among three groups is shown in Figure 10.
FIGURE 10. Volcano maps of differentially expressed mRNAs between groups. (A) MTP vs. Control (B) MTP + CR vs. MTP.
Compared with the Control group, 1,148 mRNAs were identified to be differently expressed in the MTP groups. Furthermore, 1,526 mRNAs were differentially expressed in the MTP + CR group compared with the MTP group (Figure 11A). There were 76 differentially expressed mRNAs identified in the MTP group compared with Control group as well as in the MTP + CR group compared with MTP group, which were also associated with hepatotoxicity. Kyoto Encyclopedia of Genes and Genomes analysis showed that the differentially expressed mRNAs related to hepatotoxicity were mainly enriched in the complement and coagulation cascades, p53 signaling pathway, glutathione metabolism, IL-17 signaling pathway, and drug metabolism-cytochrome P450 (Figure 11B).
FIGURE 11. Venn diagram showing the number of differently expressed mRNAs related to hepatotoxicity (A) and pathway enrichment analysis (B).
3.7 Validation of RNA-Seq Results Using qRT-PCR
Expression of mRNA was restricted to FPKM > 20, which resulted in selection of 23 DEGs. Analysis of the expression trends of the top 23 DEGs (Figure 12) resulted in selection of Cyp1a2, Gstp1, and Gsta4, which were related to drug metabolism-cytochrome P450 and glutathione metabolism, for further qRT-PCR verification. As shown in Figure 13, Cyp1a2, Gsta4, and Gstp1 expression levels were decreased in the MTP group, and these decreases were mitigated in the MTP + CR group.
FIGURE 13. Confirmation of mRNA expression by qRT-PCR (A) the CYP1A2 mRNA level; (B) the GSTP1 mRNA level; (C) the GSTA4 mRNA level. **p < 0.01,***p < 0.001 vs MTP.
4 Discussion
The therapeutic window for TP is very narrow, resulting in sometimes overlapping therapeutic and toxic ranges. Therefore, identification of methods to attenuate toxicity without impacting efficacy is of great importance.
Previous studies showed that crocin has a considerable anti-inflammatory and antioxidant potency (Li et al., 2018; Korani et al., 2019; Yaribeygi et al., 2021). In addition, combined treatment with GA and TP increase efficacy while decreasing toxicity in RA treatment (Tai et al., 2014). Therefore, in this study, we explored the ability of the novel treatment combination of TP + CR to treat arthritis with reduced TP-induced toxicity using GA combined with TP as the positive control. As a result, the anti-arthritis effects in the TP + CR group were equivalent to those in the TP and TP + GA groups, as determined by evaluation of foot volume and arthritis score, proinflammatory cytokine levels, and collagen antibody assay. Animal toxicity experiments showed that CR reduced TP-induced multi-organ damage (Figure 8 and Table 4), and reduced mortality.
Hepatotoxicity is the most significant TP-induced side effect and the mechanism is complex, which is believed to occur via oxidative stress, abnormal liver drug enzyme activity, and immune-mediated injury (Tian et al., 2019). Crocin has been shown to act on multiple pharmacological targets, such as antioxidant, anti-inflammatory, and immunoregulatory systems that may be involved in TP-induced toxicity (Attia et al., 2021).
Previous animal studies have shown that crocin is a protective against doxorubicin-induced nephrotoxicity and cyclophosphamide-induced hepatotoxicity through modulation of antioxidant enzymes and inflammatory mediators (Jnaneshwari et al., 2013; Hussain et al., 2021). Combined treatment with vitamin C and TP could combat oxidative stress by regulating the levels of SOD, GSH, CAT and MD (Xu et al., 2019), which agrees with the known mechanisms for TP-induced hepatotoxicity (Cao et al., 2022). TP may lead to emergency oxidative damage of liver cells by reducing thioredoxin activity (Shen et al., 2019). In this study, we evaluated changes in oxidative stress markers in the liver, the primary organ responsible for drug metabolism. The results showed that co-administration of TP + CR reversed TP-induced changes in SOD and CAT activities, and GSH and MDA levels, in a dose-dependent manner.
The metabolism of TP and other drugs depends on enzymes in liver microsomes, which involve phase I and phase II metabolism. Cytochrome P450s, representative enzymes of Phase I, are responsible for the hydroxylation of triptolide in vitro and CYP3A4 enzyme mediated metabolic elimination is an important detoxification pathway for TP (Xiao et al., 2020). Glutathione-S-transferases are a superfamily of phase-II metabolic enzymes that protect against oxidative stress (Singh and Reindl, 2021). Transcriptome sequencing and KEGG analysis in this study showed that differentially expressed mRNAs related to hepatotoxicity (76 mRNAs) were mainly enriched in glutathione metabolism, IL-17 signaling pathway, and drug metabolism-cytochrome P450. We selected the most significantly differentially expressed genes, Cyp1a2, Gstp1, and Gsta4, for confirmation by qRT-PCR. Our results showed that co-administration of TP + CR reversed TP-induced decreased in Cyp1a2, Gsta4, and Gstp1 expression. Cyp1a2 is an important phase-I metabolic enzyme in the cytochrome P450 family of enzymes. Gsta4 and Gstp1 can catalyze the binding of glutathione to TP metabolites in vivo, thus reducing the toxicity of TP. Therefore, our results indicated that phase I and phase II metabolic enzymes both participate in critical detoxification processes in TP-induced liver injury, and crocin could reduce TP-induced liver injury by down-regulating gene expression of these enzymes. In addition, IL-17 mediated the immune response of TP and played an essential role in the liver injury pathology (Wei et al., 2017). Our results also revealed that crocin might be involved in IL-17 mediated immune regulation. However, further research is still required.
In conclusion, our results demonstrated that co-administration of TP and CR could protect CIA mice from TP-induced multi-organ damage without reducing the therapeutic efficacy of TP. The mechanisms by which CR protected against TP-induced toxicity may have been related to the drug metabolism-cytochrome P450 and glutathione metabolism pathways. Our study demonstrated that CR could be used to attenuate TP toxicity without impacting therapeutic efficacy. Future studies should clarify the specific mechanisms by which CR protects against TP-induced toxicity, and ongoing studies are exploring new dosage forms and administration strategies for CR and TP.
Data Availability Statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ncbi.nlm.nih.gov/geo/, GSE202175
Ethics Statement
The animal study was reviewed and approved by the Animal Ethics Committee In Henan University of Chinese Medicine.
Author Contributions
MY and YY performed the experiments, analyzed the data, prepared figures and/or tables, and authored or reviewed drafts of the paper. ZZ conceived the experiments and approved the final draft. GW, WS and MJ performed the experiments, samples collection, and approved the final draft. JZ, XW and HZ conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.
Funding
This study was sponsored by National Natural Science Foundation of China (21601053, U1604185), Henan Scientific and technological Innovation Talents Project (20HASTIT050), Henan Science Fund for Excellent Young Scholars (212300410057), the Scientific and Technological Brainstorm Project of Henan Province (202102310515), Innovative Research Team in Science and Technology of Henan Province (211RTSTHN026), Henan provincial Key Scientific Research Projects (22102310638), Henan Scientific Research Funding Project for Overseas Staffs 2020 (No: 29).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Abdi, H., Aganj, Z., Hosseinzadeh, H., and Mosaffa, F. (2022). Crocin Restores the Balance of Th1/Th2 Immune Cell Response in ConA-Treated Human Lymphocytes. Pharmacol. Rep. 74, 513–522. [Preprint]. doi:10.1007/s43440-022-00362-3
Attia, A. A., Ramdan, H. S., Al-Eisa, R. A., Adle Fadle, B. O. A., and El-Shenawy, N. S. (2021). Effect of Saffron Extract on the Hepatotoxicity Induced by Copper Nanoparticles in Male Mice. Molecules 26 (10), 3045. doi:10.3390/molecules26103045
Brand, D. D., Latham, K. A., and Rosloniec, E. F. (2007). Collagen-induced Arthritis. Nat. Protoc. 2 (5), 1269–1275. doi:10.1038/nprot.2007.173
Cao, Z., Liu, B., Li, L., Lu, P., Yan, L., and Lu, C. (2022). Detoxification Strategies of Triptolide Based on Drug Combinations and Targeted Delivery Methods. Toxicology 469, 153134. doi:10.1016/j.tox.2022.153134
El-Beshbishy, H. A., Hassan, M. H., Aly, H. A., Doghish, A. S., and Alghaithy, A. A. (2012). Crocin "saffron" Protects against Beryllium Chloride Toxicity in Rats through Diminution of Oxidative Stress and Enhancing Gene Expression of Antioxidant Enzymes. Ecotoxicol. Environ. Saf. 83, 47–54. doi:10.1016/j.ecoenv.2012.06.003
Hosseini, A., Razavi, B. M., and Hosseinzadeh, H. (2018). Pharmacokinetic Properties of Saffron and its Active Components. Eur. J. Drug. Metab. Pharmacokinet. 43 (4), 383–390. doi:10.1007/s13318-017-0449-3
Hussain, M. A., Abogresha, N. M., AbdelKader, G., Hassan, R., Abdelaziz, E. Z., and Greish, S. M. (2021). Antioxidant and Anti-inflammatory Effects of Crocin Ameliorate Doxorubicin-Induced Nephrotoxicity in Rats. Oxid. Med. Cell. Longev. 2021, 8841726. doi:10.1155/2021/8841726
Jnaneshwari, S., Hemshekhar, M., Santhosh, M. S., Sunitha, K., Thushara, R., Thirunavukkarasu, C., et al. (2013). Crocin, a Dietary Colorant, Mitigates Cyclophosphamide-Induced Organ Toxicity by Modulating Antioxidant Status and Inflammatory Cytokines. J. Pharm. Pharmacol. 65 (4), 604–614. doi:10.1111/jphp.12016
Korani, S., Korani, M., Sathyapalan, T., and Sahebkar, A. (2019). Therapeutic Effects of Crocin in Autoimmune Diseases: A Review. BioFactors 45 (6), 835–843. doi:10.1002/biof.1557
Li, L., Zhang, H., Jin, S., and Liu, C. (2018). Effects of Crocin on Inflammatory Activities in Human Fibroblast-like Synoviocytes and Collagen-Induced Arthritis in Mice. Immunol. Res. 66 (3), 406–413. doi:10.1007/s12026-018-8999-2
Liang, H., Peng, B., Dong, C., Liu, L., Mao, J., Wei, S., et al. (2018). Cationic Nanoparticle as an Inhibitor of Cell-free DNA-Induced Inflammation. Nat. Commun. 9 (1), 4291. doi:10.1038/s41467-018-06603-5
Qin, W. Z. (2019). “Chapter 2 Rheumatoid Arthritis,” in The Study on Tripterygium Wilfordii. Editor S Tu (BeiJing, China: science press), 378–387.
Razavi, B. M., and Hosseinzadeh, H. (2015). Saffron as an Antidote or a Protective Agent against Natural or Chemical Toxicities. Daru 23 (1), 31. doi:10.1186/s40199-015-0112-y
Salem, M., Shaheen, M., Tabbara, A., and Borjac, J. (2022). Saffron Extract and Crocin Exert Anti-inflammatory and Anti-oxidative Effects in a Repetitive Mild Traumatic Brain Injury Mouse Model. Sci. Rep. 12 (1), 5004. doi:10.1038/s41598-022-09109-9
Shen, F., Xiong, Z., Kong, J., Wang, L., Cheng, Y., Jin, J., et al. (2019). Triptolide Impairs Thioredoxin System by Suppressing Notch1-Mediated PTEN/Akt/Txnip Signaling in Hepatocytes. Toxicol. Lett. 300, 105–115. doi:10.1016/j.toxlet.2018.10.024
Singh, R. R., and Reindl, K. M. (2021). Glutathione S-Transferases in Cancer. Antioxidants (Basel) 10 (5), 701. doi:10.3390/antiox10050701
Tai, T., Huang, X., Su, Y., Ji, J., Su, Y., Jiang, Z., et al. (2014). Glycyrrhizin Accelerates the Metabolism of Triptolide through Induction of CYP3A in Rats. J. Ethnopharmacol. 152 (2), 358–363. doi:10.1016/j.jep.2014.01.026
Tan, Q. Y., Hu, Q., Zhu, S. N., Jia, L. L., Xiao, J., Su, H. Z., et al. (2018). Licorice Root Extract and Magnesium Isoglycyrrhizinate Protect against Triptolide-Induced Hepatotoxicity via Up-Regulation of the Nrf2 Pathway. Drug. Deliv. 25 (1), 1213–1223. doi:10.1080/10717544.2018.1472676
Tian, Y., Li, P., Xiao, Z., Zhou, J., Xue, X., Jiang, N., et al. (2021). Triptolide Inhibits Epithelial-Mesenchymal Transition Phenotype through the p70S6k/GSK3/β-Catenin Signaling Pathway in Taxol-Resistant Human Lung Adenocarcinoma. Transl. Lung. Cancer. Res. 10 (2), 1007–1019. doi:10.21037/tlcr-21-145
Tian, Y. G., Su, X. H., Liu, L. L., Kong, X. Y., and Lin, N. (2019). Overview of Hepatotoxicity Studies on Tripterygium Wilfordii in Recent 20 Years. Zhongguo. Zhong. Yao. Za. Zhi. 44 (16), 3399–3405. doi:10.19540/j.cnki.cjcmm.20190527.408
Tong, L., Zhao, Q., Datan, E., Lin, G. Q., Minn, I., Pomper, M. G., et al. (2021). Triptolide: Reflections on Two Decades of Research and Prospects for the Future. Nat. Prod. Rep. 38 (4), 843–860. doi:10.1039/d0np00054j
Trentham, D. E., Townes, A. S., and Kang, A. H. (1977). Autoimmunity to Type II Collagen an Experimental Model of Arthritis. J. Exp. Med. 146 (3), 857–868. doi:10.1084/jem.146.3.857
Wang, J. M., Chen, R. X., Zhang, L. L., Ding, N. N., Liu, C., Cui, Y., et al. (2018). In Vivo protective Effects of Chlorogenic Acid against Triptolide-Induced Hepatotoxicity and its Mechanism. Pharm. Biol. 56, 626–631. doi:10.1080/13880209.2018.1527370
Wei, C. B., Tao, K., Jiang, R., Zhou, L. D., Zhang, Q. H., and Yuan, C. S. (2017). Quercetin Protects Mouse Liver against Triptolide-Induced Hepatic Injury by Restoring Th17/Treg Balance through Tim-3 and TLR4-MyD88-NF-Κb Pathway. Int. Immunopharmacol. 53, 73–82. doi:10.1016/j.intimp.2017.09.026
Xiao, X., Zhang, T., Huang, J., Zhao, Q., and Li, F. (2020). Effect of CYP3A4 on Liver Injury Induced by Triptolide. Biomed. Chromatogr. 34, e4864. doi:10.1002/bmc.4864
Xing, B., Li, S., Yang, J., Lin, D., Feng, Y., Lu, J., et al. (2021). Phytochemistry, Pharmacology, and Potential Clinical Applications of Saffron: A Review. J. Ethnopharmacol. 281, 114555. doi:10.1016/j.jep.2021.114555
Xu, P., Li, Y., Yu, Z., Yang, L., Shang, R., and Yan, Z. (2019). Protective Effect of Vitamin C on Triptolide-Induced Acute Hepatotoxicity in Mice through Mitigation of Oxidative Stress. An. Acad. Bras. Cienc. 91, e20181257. doi:10.1590/0001-3765201920181257
Xu, Z., Lin, S., Tong, Z., Chen, S., Cao, Y., Li, Q., et al. (2022). Crocetin Ameliorates Non-alcoholic Fatty Liver Disease by Modulating Mitochondrial Dysfunction in L02 Cells and Zebrafish Model. J. Ethnopharmacol. 285, 114873. doi:10.1016/j.jep.2021.114873
Yabe, R., Chung, S. H., Murayama, M. A., Kubo, S., Shimizu, K., Akahori, Y., et al. (2021). TARM1 Contributes to Development of Arthritis by Activating Dendritic Cells through Recognition of Collagens. Nat. Commun. 12, 94. doi:10.1038/s41467-020-20307-9
Yalikong, A., Li, X. Q., Zhou, P. H., Qi, Z. P., Li, B., Cai, S. L., et al. (2021). A Triptolide Loaded HER2-Targeted Nano-Drug Delivery System Significantly Suppressed the Proliferation of HER2-Positive and BRAF Mutant Colon Cancer. Int. J. Nanomedicine. 16, 2323–2335. doi:10.2147/IJN.S287732
Yang, G., Wang, L., Yu, X., Huang, Y., Qu, C., Zhang, Z., et al. (2017). Protective Effect of 18β-Glycyrrhetinic Acid against Triptolide-Induced Hepatotoxicity in Rats. Evidence-Based Complementary Altern. Med. 2017, 3470320. doi:10.1155/2017/3470320
Yaribeygi, H., Maleki, M., Mohammadi, M. T., Sathyapalan, T., Jamialahmadi, T., and Sahebkar, A. (2021). Crocin Improves Diabetes-Induced Oxidative Stress via Downregulating the Nox-4 in Myocardium of Diabetic Rats. Adv. Exp. Med. Biol. 1328, 275–285. doi:10.1007/978-3-030-73234-9_18
Zeng, H., Zhu, X., Tian, Q., Yan, Y., Zhang, L., Yan, M., et al. (2020). In Vivo antitumor Effects of Carboxymethyl Chitosan-Conjugated Triptolide after Oral Administration. Drug. Deliv. 27, 848–854. doi:10.1080/10717544.2020.1770370
Zhang, L., Yan, M., Chen, K., Tian, Q., Song, J., Zhang, Z., et al. (2020). Novel Carboxylated Chitosan-Based Triptolide Conjugate for the Treatment of Rheumatoid Arthritis. Pharmaceutics 12 (3), 202. doi:10.3390/pharmaceutics12030202
Zhang, Y., Fei, F., Zhen, L., Zhu, X., Wang, J., Li, S., et al. (2017). Sensitive Analysis and Simultaneous Assessment of Pharmacokinetic Properties of Crocin and Crocetin after Oral Administration in Rats. J. Chromatogr. B. Anal. Technol. Biomed. Life. Sci. 1044-1045, 1–7. doi:10.1016/j.jchromb.2016.12.003
Zhang, Y., Mao, X., Li, W., Chen, W., Wang, X., Ma, Z., et al. (2021). Tripterygium Wilfordii: An Inspiring Resource for Rheumatoid Arthritis Treatment. Med. Res. Rev. 41, 1337–1374. doi:10.1002/med.21762
Zhao, J., Zhang, F., Xiao, X., Wu, Z., Hu, Q., Jiang, Y., et al. (2021). Tripterygium Hypoglaucum (Levl.) Hutch and its Main Bioactive Components: Recent Advances in Pharmacological Activity, Pharmacokinetics and Potential Toxicity. Front. Pharmacol. 12, 715359. doi:10.3389/fphar.2021.715359
Keywords: triptolide, crocin, compatibility, toxicity, arthritis
Citation: Yan M, Yan Y, Zhang Z, Wang G, Shi W, Jiang M, Zhao J, Wu X and Zeng H (2022) The Effect of Triptolide Combined With Crocin on Arthritis in Mice: From Side Effect Attenuation to Therapy. Front. Pharmacol. 13:908227. doi: 10.3389/fphar.2022.908227
Received: 30 March 2022; Accepted: 01 June 2022;
Published: 23 June 2022.
Edited by:
Qi Wang, Harbin Medical University, ChinaReviewed by:
Amany Mohammed Gad, Sinai University, EgyptQuan Xia, First Affiliated Hospital of Anhui Medical University, China
Copyright © 2022 Yan, Yan, Zhang, Wang, Shi, Jiang, Zhao, Wu and Zeng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Junwei Zhao, anVud2Vpemhhb0BhbHVtbmkuc2p0dS5lZHUuY24=; Xiangxiang Wu, d3V4eC00MTVAMTI2LmNvbQ==; Huahui Zeng, aGh6ZW5nQGhhY3RjbS5lZHUuY24=
†These authors have contributed equally to this work